blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3197880

EP3197880 - SUBSTITUTED OXOPYRIDINE DERIVATIVES WITH ANTI-INFLAMMATORY AND ANTI-THROMBOTIC EFFECT [Right-click to bookmark this link]
Former [2017/31]SUBSTITUTED OXOPYRIDINE DERIVATIVES
[2018/20]
StatusNo opposition filed within time limit
Status updated on  30.08.2019
Database last updated on 30.09.2024
FormerThe patent has been granted
Status updated on  21.09.2018
FormerGrant of patent is intended
Status updated on  01.05.2018
FormerRequest for examination was made
Status updated on  30.06.2017
FormerThe international publication has been made
Status updated on  20.03.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
[2017/31]
Inventor(s)01 / ROEHRIG, Susanne
Dietrich-Bonhoeffer-Str. 66
40724 Hilden / DE
02 / HILLISCH, Alexander
Stöckerberg 3-5
42651 Solingen / DE
03 / HEITMEIER, Stefan
Am Wasserturm 56
42489 Wülfrath / DE
04 / SCHMIDT, Martina Victoria
Düsseldorfer Str. 75
51063 Köln / DE
05 / SCHLEMMER, Karl-Heinz
Wildsteig 22a
42113 Wuppertal / DE
06 / TERSTEEGEN, Adrian
Rübezahlweg 8
42111 Wuppertal / DE
07 / TELLER, Henrik
Alte Weide 40a
18258 Schwaan / DE
 [2017/31]
Representative(s)BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 50
40789 Monheim am Rhein / DE
[N/P]
Former [2017/31]BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 10
40789 Monheim am Rhein / DE
Application number, filing date15777624.622.09.2015
[2017/31]
WO2015EP71650
Priority number, dateEP2014018608124.09.2014         Original published format: EP 14186081
[2017/31]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2016046159
Date:31.03.2016
Language:DE
[2016/13]
Type: A1 Application with search report 
No.:EP3197880
Date:02.08.2017
Language:DE
The application published by WIPO in one of the EPO official languages on 31.03.2016 takes the place of the publication of the European patent application.
[2017/31]
Type: B1 Patent specification 
No.:EP3197880
Date:24.10.2018
Language:DE
[2018/43]
Search report(s)International search report - published on:EP31.03.2016
ClassificationIPC:C07D401/12, C07D405/06, C07D213/69, A61P7/02, A61P29/00, A61P1/04, A61P27/02, A61K31/4418, A61K31/4439, A61K31/4545, A61K31/496, A61K9/20
[2018/20]
CPC:
C07D213/69 (EP,US); A61K31/00 (EP,US); A61K47/36 (EP,US);
A61K9/0048 (EP,US); A61K9/0095 (EP,US); A61K9/2018 (EP,US);
A61K9/2027 (EP,US); A61K9/2059 (EP,US); A61P1/04 (EP,US);
A61P27/02 (EP,US); A61P29/00 (EP,US); A61P7/02 (EP,US);
C07D401/12 (EP,US); C07D405/06 (EP,US) (-)
Former IPC [2017/31]C07D401/12, C07D405/06, C07D213/69, A61K31/4418, A61K31/4439, A61K31/4545, A61K31/496, A61P7/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/31]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:SUBSTITUIERTE OXOPYRIDIN-DERIVATE MIT ANTI-INFLAMMATORISCHER UND ANTI-THROMBOTISCHER WIRKUNG[2018/20]
English:SUBSTITUTED OXOPYRIDINE DERIVATIVES WITH ANTI-INFLAMMATORY AND ANTI-THROMBOTIC EFFECT[2018/20]
French:DÉRIVÉS D'OXOPYRIDINE SUBSTITUÉS À EFFET ANTI-INFLAMMATOIRE ET ANTI-THROMBOTIQUE[2018/20]
Former [2017/31]SUBSTITUIERTE OXOPYRIDIN-DERIVATE
Former [2017/31]SUBSTITUTED OXOPYRIDINE DERIVATIVES
Former [2017/31]DÉRIVÉS D'OXOPYRIDINE SUBSTITUÉS
Entry into regional phase24.04.2017National basic fee paid 
24.04.2017Designation fee(s) paid 
24.04.2017Examination fee paid 
Examination procedure20.03.2017Date on which the examining division has become responsible
24.04.2017Examination requested  [2017/31]
15.11.2017Amendment by applicant (claims and/or description)
02.05.2018Communication of intention to grant the patent
27.08.2018Fee for grant paid
27.08.2018Fee for publishing/printing paid
27.08.2018Receipt of the translation of the claim(s)
Opposition(s)25.07.2019No opposition filed within time limit [2019/40]
Fees paidRenewal fee
12.09.2017Renewal fee patent year 03
11.09.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.09.2015
AL24.10.2018
CY24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
MK24.10.2018
MT24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
TR24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
[2022/31]
Former [2021/34]HU22.09.2015
AL24.10.2018
CY24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
MT24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
TR24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2021/33]HU22.09.2015
AL24.10.2018
CY24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
TR24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2021/26]AL24.10.2018
CY24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
TR24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2020/25]AL24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
TR24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2020/17]AL24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
TR24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/50]AL24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/40]AL24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SK24.10.2018
SM24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/37]AL24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SM24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/35]AL24.10.2018
CZ24.10.2018
DK24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RS24.10.2018
SE24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/34]AL24.10.2018
DK24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RS24.10.2018
SE24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/26]AL24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RS24.10.2018
SE24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/25]FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RS24.10.2018
SE24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
Former [2019/24]FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
SE24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
Former [2019/23]FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
BG24.01.2019
NO24.01.2019
IS24.02.2019
Former [2019/22]FI24.10.2018
LT24.10.2018
NL24.10.2018
PL24.10.2018
BG24.01.2019
NO24.01.2019
IS24.02.2019
Former [2019/21]FI24.10.2018
LT24.10.2018
NL24.10.2018
NO24.01.2019
IS24.02.2019
Former [2019/20]LT24.10.2018
NL24.10.2018
NO24.01.2019
Former [2019/17]NL24.10.2018
Cited inInternational search[A]EP1526131  (GRAFFINITY PHARMACEUTICALS AG [DE]) [A] 1-14* paragraph [0141]; claims 1,22; table 3 *;
 [A]WO2013056034  (SQUIBB BRISTOL MYERS CO [US]) [A] 1-14 * paragraph [0132]; claims 1,11; table 1 *;
 [IP]WO2015120777  (SICHUAN HAISCO PHARMACEUTICAL CO LTD [CN]) [IP] 1-14 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.